The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis

Nancy L. Hordvik, Paul Henry Sammut, C. Gerald Judy, Sandra J. Strizek, John Louis Colombo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo. Aerosols were administered with the first three of four chest physiotherapy sessions given 4 h apart. Spirometry was measured before and 45 min after 7:00 A.M. and 3:00 P.M. therapy and before therapy at 7:00 P.M. and 7:00 A.M. the next morning. The mean percent change in FVC, FEV1, and FEF25-75% at 7:00 A.M. was 10.7, 14.8, and 19.6% with albuterol versus 2.4, 1.0, and -0.8% with placebo (p = 0.0012, < 0.0001, and = 0.003, respectively). A greater than 8% change in FEV1 separated changes with albuterol versus placebo with 96% specificity and occurred in 75% of all patients with albuterol; 71% at 7:00 A.M. versus 24% at 3:00 P.M. The reduction in response at 3:00 P.M. (p < 0.01) was presumably due to prolonged effects of morning therapy (> 4 h). Individual changes in spirometry were significantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M. The mean percent change for the FVC, FEV1, and FEF25-75 across the day (7:00 A.M pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versus 3.9, 3.5, and 2.6% with placebo (p = 0.029, 0.036, and 0.232, respectively). The more positive and homogeneous changes in spirometry with albuterol, along with greater changes in these measures across the day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of hospitalized patients with cystic fibrosis.

Original languageEnglish (US)
Pages (from-to)156-160
Number of pages5
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume154
Issue number1
DOIs
StatePublished - Jan 1 1996

Fingerprint

Albuterol
Cystic Fibrosis
Placebos
Lung
Spirometry
Aerosols
Cross-Over Studies
Inhalation
Thorax
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis. / Hordvik, Nancy L.; Sammut, Paul Henry; Judy, C. Gerald; Strizek, Sandra J.; Colombo, John Louis.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 154, No. 1, 01.01.1996, p. 156-160.

Research output: Contribution to journalArticle

@article{bda43d7bda584edb9717383299796b52,
title = "The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis",
abstract = "Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo. Aerosols were administered with the first three of four chest physiotherapy sessions given 4 h apart. Spirometry was measured before and 45 min after 7:00 A.M. and 3:00 P.M. therapy and before therapy at 7:00 P.M. and 7:00 A.M. the next morning. The mean percent change in FVC, FEV1, and FEF25-75{\%} at 7:00 A.M. was 10.7, 14.8, and 19.6{\%} with albuterol versus 2.4, 1.0, and -0.8{\%} with placebo (p = 0.0012, < 0.0001, and = 0.003, respectively). A greater than 8{\%} change in FEV1 separated changes with albuterol versus placebo with 96{\%} specificity and occurred in 75{\%} of all patients with albuterol; 71{\%} at 7:00 A.M. versus 24{\%} at 3:00 P.M. The reduction in response at 3:00 P.M. (p < 0.01) was presumably due to prolonged effects of morning therapy (> 4 h). Individual changes in spirometry were significantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M. The mean percent change for the FVC, FEV1, and FEF25-75 across the day (7:00 A.M pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7{\%} with albuterol versus 3.9, 3.5, and 2.6{\%} with placebo (p = 0.029, 0.036, and 0.232, respectively). The more positive and homogeneous changes in spirometry with albuterol, along with greater changes in these measures across the day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of hospitalized patients with cystic fibrosis.",
author = "Hordvik, {Nancy L.} and Sammut, {Paul Henry} and Judy, {C. Gerald} and Strizek, {Sandra J.} and Colombo, {John Louis}",
year = "1996",
month = "1",
day = "1",
doi = "10.1164/ajrccm.154.1.8680672",
language = "English (US)",
volume = "154",
pages = "156--160",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "1",

}

TY - JOUR

T1 - The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis

AU - Hordvik, Nancy L.

AU - Sammut, Paul Henry

AU - Judy, C. Gerald

AU - Strizek, Sandra J.

AU - Colombo, John Louis

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo. Aerosols were administered with the first three of four chest physiotherapy sessions given 4 h apart. Spirometry was measured before and 45 min after 7:00 A.M. and 3:00 P.M. therapy and before therapy at 7:00 P.M. and 7:00 A.M. the next morning. The mean percent change in FVC, FEV1, and FEF25-75% at 7:00 A.M. was 10.7, 14.8, and 19.6% with albuterol versus 2.4, 1.0, and -0.8% with placebo (p = 0.0012, < 0.0001, and = 0.003, respectively). A greater than 8% change in FEV1 separated changes with albuterol versus placebo with 96% specificity and occurred in 75% of all patients with albuterol; 71% at 7:00 A.M. versus 24% at 3:00 P.M. The reduction in response at 3:00 P.M. (p < 0.01) was presumably due to prolonged effects of morning therapy (> 4 h). Individual changes in spirometry were significantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M. The mean percent change for the FVC, FEV1, and FEF25-75 across the day (7:00 A.M pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versus 3.9, 3.5, and 2.6% with placebo (p = 0.029, 0.036, and 0.232, respectively). The more positive and homogeneous changes in spirometry with albuterol, along with greater changes in these measures across the day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of hospitalized patients with cystic fibrosis.

AB - Twenty-four hospitalized patients with cystic fibrosis were enrolled into a 2-d, double-blind, placebo-controlled, randomized crossover trial comparing albuterol inhalation aerosol with a saline placebo. Aerosols were administered with the first three of four chest physiotherapy sessions given 4 h apart. Spirometry was measured before and 45 min after 7:00 A.M. and 3:00 P.M. therapy and before therapy at 7:00 P.M. and 7:00 A.M. the next morning. The mean percent change in FVC, FEV1, and FEF25-75% at 7:00 A.M. was 10.7, 14.8, and 19.6% with albuterol versus 2.4, 1.0, and -0.8% with placebo (p = 0.0012, < 0.0001, and = 0.003, respectively). A greater than 8% change in FEV1 separated changes with albuterol versus placebo with 96% specificity and occurred in 75% of all patients with albuterol; 71% at 7:00 A.M. versus 24% at 3:00 P.M. The reduction in response at 3:00 P.M. (p < 0.01) was presumably due to prolonged effects of morning therapy (> 4 h). Individual changes in spirometry were significantly more positive and homogeneous with albuterol versus placebo at both 7:00 A.M. and 3:00 P.M. The mean percent change for the FVC, FEV1, and FEF25-75 across the day (7:00 A.M pretherapy to 7:00 P.M. pretherapy) was 8.1, 10.1, and 9.7% with albuterol versus 3.9, 3.5, and 2.6% with placebo (p = 0.029, 0.036, and 0.232, respectively). The more positive and homogeneous changes in spirometry with albuterol, along with greater changes in these measures across the day when compared with placebo, suggest that albuterol improves pulmonary function in a majority of hospitalized patients with cystic fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=0030017497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030017497&partnerID=8YFLogxK

U2 - 10.1164/ajrccm.154.1.8680672

DO - 10.1164/ajrccm.154.1.8680672

M3 - Article

C2 - 8680672

AN - SCOPUS:0030017497

VL - 154

SP - 156

EP - 160

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 1

ER -